Table 2.
Effectiveness of three consecutive monthly doses of Credelio Plus® and afoxolaner + milbemycin oxime based on investigator counts of natural flea infestations for all flea species on client owned dogs in European field study
| Study day | Treatment group | n | Live flea counts | % Effectiveness | |
|---|---|---|---|---|---|
| Range | Arithmetic mean | ||||
| 0 | Credelio Plus® | 135 | 5–100 | 11.8 | – |
| Afoxolaner + Milbemycin oxime | 67 | 5–139 | 11.4 | – | |
| 14 ± 2 | Credelio Plus® | 130 | 0–12 | 0.15 | 98.7 |
| Afoxolaner + Milbemycin oxime | 66 | 0–6 | 0.17 | 98.5 | |
| 28 ± 2 | Credelio Plus® | 132 | 0–3 | 0.05 | 99.6 |
| Afoxolaner + Milbemycin oxime | 66 | 0–20 | 0.32 | 97.2 | |
| 56 ± 2 | Credelio Plus® | 131 | 0–0 | 0 | 100 |
| Afoxolaner + Milbemycin oxime | 65 | 0–3 | 0.05 | 99.6 | |
| 84 ± 2 | Credelio Plus® | 126 | 0–0 | 0 | 100 |
| Afoxolaner + Milbemycin oxime | 65 | 0–0 | 0 | 100 | |